EDAP TMS ( (EDAP) ) just unveiled an update.
On March 3, 2025, EDAP TMS announced the appointment of Glen French to its Board of Directors. French, a seasoned executive with over 25 years in medical device development, is expected to enhance EDAP’s strategic decision-making as the company seeks to expand its Focal One platform beyond prostate cancer to other therapeutic areas. His extensive experience in leading medical technology companies, including a successful tenure at Pulmonx Corporation, positions him to contribute significantly to EDAP’s growth and innovation efforts.
More about EDAP TMS
EDAP TMS is a recognized leader in robotic energy-based therapies, developing, manufacturing, and distributing minimally invasive medical devices worldwide. The company specializes in ultrasound technology, offering products like the Focal One® platform for prostate focal therapy, with potential applications beyond prostate cancer.
YTD Price Performance: 6.67%
Average Trading Volume: 110,135
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $94.99M
For an in-depth examination of EDAP stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com